Laurus Labs gets USFDA nod for HIV drug

Our Bureau Hyderabad | Updated on May 19, 2020

Laurus Labs Ltd has received approval from the US Food and Drug Administration (USFDA) for two Abbreviated New Drug Applications (ANDAs ) for Tenofovir/ Lamivudine/ Efavirenz (TLE) for 400 mg and 600 mg tablets.

The approval has been given under the President’s Emergency Plan for AIDS Relief (PEPFAR), the Hyderabad-based company said in a release on Tuesday.

Laurus Labs is one of the few players in the ARV segment to receive approval for TLE 400 mg. It is “one of the most preferred regimens in the ARV first line treatment,” the company said.

Laurus has already received WHO pre-qualification for the same.

Published on May 19, 2020

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like